Seattle Genetics Inc. (SGEN) Reports In-Line Q2 EPS

Seattle Genetics Inc. (NASDAQ: SGEN) reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $48.8 million versus the consensus estimate of $50.33 million.

For earnings history and earnings-related data on Seattle Genetics Inc. (SGEN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Morgan Stanley Starts Target Hospitality (TH) at Overweight
• Apple Touched $5 Trillion and Then Gave It Back. Gabriel Adams, Senior Markets Strategist at Swiftvale, on Reading a Milestone and a Reversal in the Same Week